Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Bermejo

Showing results (61-70 of 133) with videos related to

Pageof 14
Sort By:
Inflammatory Bowel Diseases|March 18, 2009
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapseJavier P Gisbert, Fernando Bermejo, Jose-Lázaro Pérez-Calle, et al.
Hepato-Gastroenterology|December 24, 2008
Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of responseYago Gonzalez-Lama, Ignacio Fernandez-Blanco, Antonio Lopez-SanRoman, et al.
Alimentary Pharmacology & Therapeutics|May 5, 2022
Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitisCarlos Taxonera, María Jesús Fernández-Aceñero, David Olivares, et al.
The American Journal of Gastroenterology|August 12, 2010
Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurinesCarlos Teruel, Antonio López-San Román, Fernando Bermejo, et al.
Digestive Diseases and Sciences|March 11, 2018
Self-Formation Assessed by Cumulative Summation Test Does Not Reach Recommended Thresholds for Optical Diagnosis of Colorectal Polyps ≤ 7 mmFrancisco Javier García-Alonso, Isabel Manzano Santamaría, Antonio Guardiola Arévalo, et al.
European Journal of Gastroenterology & Hepatology|June 21, 2012
Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experienceYago González-Lama, Carlos Taxonera, Antonio López-Sanromán, et al.
Mediators of Inflammation|September 5, 2015
Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression ProfileLuz María Medrano, Carlos Taxonera, Cristina González-Artacho, et al.
Journal of Crohn'S & Colitis|February 18, 2015
Incidence, management, and course of cancer in patients with inflammatory bowel diseaseAlicia Algaba, Iván Guerra, Ignacio Marín-Jiménez, et al.
Journal of Clinical Gastroenterology|June 1, 2012
Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patientsJavier P Gisbert, Angeles Pérez-Aisa, Fernando Bermejo, et al.
Journal of Clinical Gastroenterology|December 9, 2014
Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapyCarlos Castaño-Milla, María Chaparro, Cristina Saro, et al.
Pageof 14

Showing results (61-70 of 133) with videos related to

Sort By:
Pageof 14
Inflammatory Bowel Diseases|March 18, 2009
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapseJavier P Gisbert, Fernando Bermejo, Jose-Lázaro Pérez-Calle, et al.
Hepato-Gastroenterology|December 24, 2008
Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of responseYago Gonzalez-Lama, Ignacio Fernandez-Blanco, Antonio Lopez-SanRoman, et al.
Alimentary Pharmacology & Therapeutics|May 5, 2022
Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitisCarlos Taxonera, María Jesús Fernández-Aceñero, David Olivares, et al.
The American Journal of Gastroenterology|August 12, 2010
Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurinesCarlos Teruel, Antonio López-San Román, Fernando Bermejo, et al.
Digestive Diseases and Sciences|March 11, 2018
Self-Formation Assessed by Cumulative Summation Test Does Not Reach Recommended Thresholds for Optical Diagnosis of Colorectal Polyps ≤ 7 mmFrancisco Javier García-Alonso, Isabel Manzano Santamaría, Antonio Guardiola Arévalo, et al.
European Journal of Gastroenterology & Hepatology|June 21, 2012
Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experienceYago González-Lama, Carlos Taxonera, Antonio López-Sanromán, et al.
Mediators of Inflammation|September 5, 2015
Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression ProfileLuz María Medrano, Carlos Taxonera, Cristina González-Artacho, et al.
Journal of Crohn'S & Colitis|February 18, 2015
Incidence, management, and course of cancer in patients with inflammatory bowel diseaseAlicia Algaba, Iván Guerra, Ignacio Marín-Jiménez, et al.
Journal of Clinical Gastroenterology|June 1, 2012
Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patientsJavier P Gisbert, Angeles Pérez-Aisa, Fernando Bermejo, et al.
Journal of Clinical Gastroenterology|December 9, 2014
Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapyCarlos Castaño-Milla, María Chaparro, Cristina Saro, et al.
Pageof 14